Methylenetetrahydrofolate reductase gene polymorphism, hyperhomocysteinemia, and cardiovascular diseases in chronic hemodialysis patients

Nephron

Volumn 90, Issue 1, 2002, Pages 43-50

  Morimoto, Kan ^a   Haneda, Takashi ^a,b,d   Okamoto, Kiyotaka ^a   Ishida, Hironori ^c   Kikuchi, Kenjiro ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

^b Nemuro City Hospital   (Japan)

^c Ishida Hospital   (Japan)

^d Nemuro City Hospital   (Japan)

Author keywords

Cardiovascular disease; Folate; Hemodialysis; Homocysteine; Methylenetetrahydrofolate reductase gene; Vitamin B12

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CYANOCOBALAMIN; DIPEPTIDYL CARBOXYPEPTIDASE; NITRIC OXIDE SYNTHASE;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CARDIOVASCULAR DISEASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA POLYMORPHISM; ENZYME LOCALIZATION; FEMALE; FOLIC ACID BLOOD LEVEL; GENOTYPE; HEMODIALYSIS; HISTORY OF MEDICINE; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK FACTOR; VITAMIN BLOOD LEVEL;

ADULT; AGED; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; FOLIC ACID; GENOTYPE; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE, CHRONIC; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; OXIDOREDUCTASES ACTING ON CH-NH GROUP DONORS; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC; RENAL DIALYSIS; RISK FACTORS; STATISTICS; VITAMIN B 12;

EID: 0036137128     PISSN: 00282766     EISSN: None     Source Type: Journal    
DOI: 10.1159/000046313     Document Type: Article

References (32)

1. Cardiovascular mortality and morbidity in dialysis patients
2. USRDS 1997 Annual Data Report. VI. Causes of death
3. The deletion/insertion polymorphism of the angiotensin converting enzyme gene and cardiovascular-renal risk
4. Association of a polymorphism of the endothelial constitutive nitric oxide synthase gene with myocardial infarction in the Japanese population
5. Nitric oxide synthase gene polymorphism and its influence on cardiovascular disease
6. Usefulness of the I/D angiotensin-converting enzyme genotype for detecting the risk of left ventricular hypertrophy in pharmacologically treated hypertensive men
7. Antihypertensive treatment modulates the association between the D/I ACE gene polymorphism and left ventricular hypertrophy: A meta-analysis
8. Angiotensin I-converting enzyme gene insertion/deletion and angiotensinogen M235T polymorphism: Risk of chronic renal failure
9. Insertion/deletion polymorphism in intron 16 of the ACE gene and left ventricular hypertrophy in patients with end-stage renal disease
10. Polymorphism of the angiotensin-converting enzyme gene in end-stage renal failure patients
11. No association between deletion-type angiotensin-converting enzyme gene polymorphism and left ventricular hypertrophy in hemodialysis patients
12. Relationship between erythropoietin administration and the endothelial nitric oxide synthase gene polymorphism in patients with hemodialysis
13. The common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: The result of a meta-analysis
14. Thermolabile methylenetetrahydrofolate reductase in coronary artery disease
15. Association of methylenetetrahydrofolate reductase gene polymorphism with carotid arterial wall thickening and myocardial infarction risk in NIDDM
16. An association with common polymorphism in the methylenetetrahydrofolate reductase gene: Homocysteine, carotid atherosclerosis and cardiovascular disease outcomes in patients with end-stage renal disease
17. The C677T methylenetetrahydrofolate reductase gene mutation in hemodialysis patients
18. Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients
19. Plasma homocysteine levels and mortality in patients with coronary artery disease
20. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients: A prospective study
21. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease
22. Mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients
23. High-dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients
24. Cardiovascular morbidity and endothelial dysfunction in chronic haemodialysis patients: Is homocysteine the missing link?
25. Response of hyperhomocysteinemia to folic acid supplementation in patients with end-stage renal disease
26. Evidence of altered homocysteine metabolism in chronic renal failure
27. A candidate genetic risk factor for vascular disease: A common mutation in MTHFR
28. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations
29. Homocysteine, B vitamins, and vascular-access thrombosis in patients treated with hemodialysis
30. Prevalence and determinants of hyperhomocysteinemia in hemodialysis and peritoneal dialysis
31. Hemocysteine and vascular access complications in haemodialysis patients: Insights into a complex metabolic relationship
32. Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients